Inhibition of UBA6 by inosine augments tumour immunogenicity and responses

Lei Zhang,Li Jiang,Liang Yu,Qin Li,Xiangjun Tian,Jingquan He,Ling Zeng,Yuqin Yang,Chaoran Wang,Yuhan Wei,Xiaoyue Jiang,Jing Li,Xiaolu Ge,Qisheng Gu,Jikun Li,Di Wu,Anthony J. Sadler,Di Yu,Dakang Xu,Yue Gao,Xiangliang Yuan,Baokun He

DOI: https://doi.org/10.1038/s41467-022-33116-z

IF: 16.6

2022-09-15

Nature Communications

Abstract:Abstract Anti-cancer immunity and response to immune therapy is influenced by the metabolic states of the tumours. Immune checkpoint blockade therapy (ICB) is known to involve metabolic adaptation, however, the mechanism is not fully known. Here we show, by metabolic profiling of plasma samples from melanoma-bearing mice undergoing anti-PD1 and anti-CTLA4 combination therapy, that higher levels of purine metabolites, including inosine, mark ICB sensitivity. Metabolic profiles of ICB-treated human cancers confirm the association between inosine levels and ICB sensitivity. In mouse models, inosine supplementation sensitizes tumours to ICB, even if they are intrinsically ICB resistant, by enhancing T cell-mediated cytotoxicity and hence generating an immunologically hotter microenvironment. We find that inosine directly inhibits UBA6 in tumour cells, and lower level of UBA6 makes the tumour more immunogenic and this is reflected in favourable outcome following ICB therapy in human melanomas. Transplanted mouse melanoma and breast cancer cells with genetic ablation of Uba6 show higher sensitivity to ICB than wild type tumours. Thus, we provide evidence of an inosine-regulated UBA6-dependent pathway governing tumour-intrinsic immunogenicity and hence sensitivity to immune checkpoint inhibition, which might provide targets to overcome ICB resistance.

multidisciplinary sciences